Is TB-500 Legal in Arizona? Federal Status, Prescriptions, and What Patients Need to Know

What Is TB-500 and Why Does Its Legal Status Matter?

TB-500 is a synthetic peptide derived from the naturally occurring protein thymosin beta-4 (Tβ4). The active sequence most often sold as "TB-500" corresponds to the actin-binding fragment Ac-LKKTETQ, sometimes labeled TB4-Frag or thymosin beta-4 fragment. Thymosin beta-4 itself is produced endogenously; research has linked it to cell migration, wound healing, and angiogenesis.

Because TB-500 is not FDA-approved, it cannot be marketed as a drug in the United States without going through the full New Drug Application (NDA) process under 21 U.S.C. § 355. That single regulatory fact drives nearly every access question patients in Arizona ask. The FDA's drug approval database confirms no approved application for thymosin beta-4 or TB-500 as a finished pharmaceutical.

Why "Not Approved" Does Not Mean "Automatically Illegal for Patients"

The absence of FDA approval does not make possession by a patient automatically criminal. Federal law focuses enforcement on manufacturers, distributors, and dispensers rather than end patients for unapproved drugs that are not also scheduled controlled substances. Arizona Revised Statutes Title 36, Chapter 27 (the Arizona Controlled Substances Act) does not list TB-500 or thymosin beta-4 among scheduled substances. That gap matters. A patient who receives TB-500 through a legitimate prescription from a licensed provider is not committing a state-level drug offense.

The Compounding Pathway Is Where Legal Complexity Concentrates

Compounding pharmacies are the primary legal route by which patients currently access TB-500. Two federal frameworks govern those pharmacies, and TB-500's placement on one specific list is the decisive regulatory fact.

The FDA Bulks List: The Single Most Important Regulatory Fact About TB-500

The FDA maintains separate lists of bulk drug substances that 503A and 503B facilities may or may not compound. TB-500's placement on the Category 2 bulks list for 503A pharmacies is the single most consequential regulatory detail for Arizona patients.

What the Category 2 Designation Means

Category 2 on the 503A bulks list means the FDA has evaluated the substance and identified "a significant safety concern, lack of a physicochemical characterization, or absence of any evidence of clinical utility." The FDA has not yet issued a final rule on all Category 2 substances, but placement there signals that routine compounding is restricted pending further review. The FDA's 503A bulks list, including Category 2 designations, is published on the agency's compounding guidance page.

Practically, a 503A pharmacy (a traditional compounding pharmacy) may not routinely stock and dispense TB-500 the way it dispenses, say, semaglutide base or testosterone cypionate. A pharmacist considering compounding a Category 2 substance for a specific patient must weigh that placement against the clinical necessity documented by the prescribing physician.

503B Outsourcing Facilities and TB-500

Section 503B of the Federal Food, Drug, and Cosmetic Act governs outsourcing facilities, which can produce larger batches without patient-specific prescriptions. TB-500 does not appear on the FDA-approved 503B bulks list. The current 503B bulks list is maintained by the FDA here. That absence means a registered 503B outsourcing facility cannot lawfully compound TB-500 for distribution to providers or clinics in Arizona or any other state.

What This Means in Plain Terms

• A 503A compounding pharmacy in Arizona may face significant regulatory risk if it compounds TB-500 under current FDA guidance.
• No 503B outsourcing facility can legally supply TB-500 in bulk to Arizona clinics.
• Any TB-500 dispensed in a clinical setting should be accompanied by documented medical necessity and a valid patient-specific prescription.

Arizona State Law: What the State Board of Pharmacy Actually Regulates

Arizona does not have a state-specific law that independently bans or approves TB-500. The Arizona State Board of Pharmacy (AZBOP) governs pharmacies and pharmacists operating within the state under Arizona Revised Statutes Title 32, Chapter 18. The AZBOP's compounding rules require Arizona pharmacies to comply with USP standards and federal law, meaning federal restrictions on Category 2 substances apply within Arizona's borders.

Arizona's Compounding Rules Follow Federal Lead

Arizona adopted rules aligned with the Drug Quality and Security Act (DQSA) of 2013, which created the 503A and 503B frameworks. An Arizona 503A pharmacy that compounds a Category 2 substance without adequate clinical justification could face AZBOP disciplinary action in addition to any federal enforcement. That layered risk is why most Arizona compounding pharmacies are cautious about TB-500.

The Medical Practice Act and Prescriber Authority

Under Arizona Revised Statutes Title 32, Chapter 13 (the Arizona Medical Practice Act), licensed physicians have broad authority to prescribe treatments they judge medically necessary for individual patients, including off-label and investigational agents. A physician in Arizona who documents clinical rationale for TB-500 use and writes a patient-specific prescription is exercising lawful prescriber authority. The prescription itself does not become illegal simply because the compound is on the FDA's Category 2 list. The legal exposure concentrates at the compounding pharmacy level, not the prescriber level, when all documentation is in order.

No Arizona Scheduling of TB-500

Reviewing the Arizona Controlled Substances Scheduling list under A.R.S. § 36-2512 through § 36-2516 confirms that neither thymosin beta-4 nor TB-500 nor its fragment sequence appears as a scheduled substance. This is consistent with the DEA's federal scheduling, which also does not list it. The DEA's controlled substances schedules, searchable by substance, confirm the absence of thymosin beta-4.

The Research Chemical Market: A Legal Gray Area That Carries Real Risk

A substantial online market exists for TB-500 labeled "for research use only" or "not for human consumption." Vendors selling in this space typically operate under the assumption that selling a peptide for non-human, non-clinical research is outside FDA drug enforcement jurisdiction. That assumption is only partially correct.

FDA's Position on "Research Chemical" Peptides

The FDA has consistently held that labeling a substance "for research use only" does not exempt it from drug regulations if the intended use is human administration. FDA Warning Letters to peptide suppliers have explicitly stated that marketing peptides including thymosin beta-4 derivatives for human use without approval violates 21 U.S.C. § 331. If a vendor markets TB-500 with implied or explicit claims about human health benefits, FDA views that product as an unapproved drug regardless of the label.

Purity and Safety Risks in the Gray Market

Research-grade peptides sold online are not manufactured under current Good Manufacturing Practice (cGMP) requirements that apply to pharmaceutical compounders. A 2020 analysis published by researchers examining peptide purity found significant variation in actual peptide content versus labeled content in commercially available research peptides. FDA guidance on cGMP requirements for drug manufacturers outlines the standards that gray-market research peptide suppliers bypass. Patients injecting non-cGMP peptides accept risks including bacterial contamination, endotoxin exposure, and unknown impurities.

The Legal Risk to the Arizona Patient

Purchasing TB-500 from an online research chemical vendor and self-administering it does not violate Arizona's controlled substance laws. However, the patient assumes all safety risk from unverified compounds. The vendor may be subject to FDA enforcement. The patient is not the enforcement target for possession, but they also have no recourse if the product causes harm, and no physician oversight to manage dosing or adverse effects.

How to Get TB-500 Legally in Arizona

The only legally defensible pathway for a patient in Arizona to access TB-500 is through a licensed healthcare provider who writes a patient-specific prescription that is then filled by a 503A compounding pharmacy willing to compound the substance based on documented clinical necessity.

The following decision framework outlines the steps involved:

Step 1: Establish Care With a Licensed Arizona Provider

The provider must be licensed under the Arizona Medical Practice Act or the equivalent for their profession (nurse practitioner, physician assistant under physician supervision). Telehealth consultations with Arizona-licensed providers are permitted under Arizona law, expanded significantly after 2020. The provider must document the clinical indication for TB-500, including the patient's diagnosis, prior treatments, and the rationale for choosing this investigational agent.

Step 2: Obtain a Patient-Specific Prescription

The prescription must be patient-specific. Given the 503A Category 2 designation, a blanket standing order is not sufficient. The prescription should include the compound name, concentration, volume, route of administration, dosing frequency, and the clinical indication. Many Arizona providers writing TB-500 prescriptions will include a clinical notes attachment documenting necessity.

Step 3: Work With a 503A Pharmacy That Evaluates Each Request

Not every Arizona compounding pharmacy will fill TB-500 prescriptions. Those that do will typically conduct their own review of the prescription and the clinical justification. The pharmacist has independent professional responsibility under Arizona law and may decline if they judge the request inconsistent with applicable guidelines. A provider-patient team should expect to communicate with the pharmacy directly.

Step 4: Understand Ongoing Monitoring Requirements

Because TB-500 is investigational, no standard dosing protocol has been validated in human clinical trials with regulatory-quality evidence. A physician managing a patient on TB-500 should schedule follow-up visits at a minimum of every 60 to 90 days to assess response and document any adverse effects.

Clinical Evidence Base: What Human Research Actually Shows

The honest answer is that the human evidence base for TB-500 is thin. Most published data come from animal models.

Animal and In Vitro Data

A study in the journal Cardiovascular Research (Bock-Marquette et al., 2004) demonstrated that thymosin beta-4 promoted cardiac cell migration and survival in murine myocardial infarction models. That foundational mechanistic study is indexed on PubMed. A 2010 study in Nature Medicine (Smart et al.) showed thymosin beta-4 could reactivate progenitor cells in the adult heart after ischemic injury in mice. The PubMed record for that study is available here.

Human Trial Data: Extremely Limited

As of early 2025, no Phase III randomized controlled trial has evaluated TB-500 or the TB4-Frag sequence in humans for any indication. A small Phase II trial exploring thymosin beta-4 for epidermolysis bullosa (NCT01372943) was conducted, but results were limited in scope and did not generate an FDA NDA submission. ClinicalTrials.gov records for thymosin beta-4 studies can be reviewed at the NIH clinical trials registry. The absence of Phase III data is a primary reason FDA has not approved the compound and has placed it in the Category 2 review category.

What the Guideline Bodies Say

No major U.S. Clinical guideline body, including the Endocrine Society, the American Academy of Family Physicians, or the American College of Physicians, has issued a guideline recommending TB-500 for any indication. The Endocrine Society's clinical practice guidelines, accessible through endocrine.org, do not include thymosin beta-4 peptide therapy. A physician prescribing TB-500 is doing so entirely outside of guideline-supported practice, which is legally permissible but increases documentation obligations.

Anti-Doping Status: A Separate Legal Layer for Athletes

Arizona-based athletes subject to anti-doping rules face an additional prohibition. The World Anti-Doping Agency (WADA) includes thymosin beta-4 and its fragments on the Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). The USADA, which administers anti-doping programs for U.S. Olympic and Paralympic athletes, explicitly lists TB-500 as a prohibited substance. An athlete who tests positive for thymosin beta-4 fragments faces sanctions regardless of whether the compound was obtained via a prescription from a licensed Arizona physician. A Therapeutic Use Exemption (TUE) for TB-500 is effectively impossible to obtain given the absence of an FDA-approved formulation.

Comparing TB-500's Status to Other Peptides in Arizona

Understanding TB-500's position becomes clearer when set against other peptides more commonly compounded in Arizona clinical practice.

Semaglutide base was on the 503A and 503B bulks lists for compounding during the GLP-1 shortage period, giving it a relatively clear (if temporary) compounding pathway. FDA guidance on GLP-1 shortage-based compounding is documented on the FDA drug shortage page. Sermorelin is on the FDA's 503A bulks list as a Category 1 substance for specific indications, giving it a cleaner compounding pathway than TB-500. BPC-157 shares a similarly restricted status to TB-500 under 503A rules.

The pattern is consistent: peptides with no approved human drug application and limited human safety data tend to land in Category 2 or remain unaddressed, creating legal friction at the pharmacy level even when prescriber intent is legitimate.

Documentation a Prescriber Should Maintain for TB-500 in Arizona

A physician in Arizona writing a TB-500 prescription in 2025 should maintain the following in the patient chart:

• A documented diagnosis or clinical indication with ICD-10 coding
• A record of prior treatments and why standard options were insufficient or inappropriate
• A summary of the evidence reviewed, acknowledging investigational status
• Informed consent documentation stating the patient understands TB-500 is not FDA-approved, has limited human trial data, and carries unknown long-term risks
• A plan for follow-up and outcome monitoring

The American Academy of Family Physicians provides guidance on off-label prescribing obligations that is directly applicable to investigational peptide prescribing. Thorough documentation is both an ethical obligation and practical protection if AZBOP or a liability insurer reviews the case.